BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors

In Chronic Myeloid Leukemia (CML), successful treatment requires accurate molecular monitoring to evaluate disease response and provide timely interventions for patients failing to achieve the desired outcomes. We wanted to determine whether measuring BCR-ABL1 mRNA doubling-times (DTs) could disting...

Descripción completa

Detalles Bibliográficos
Autores principales: Pennisi, Maria Stella, Stella, Stefania, Vitale, Silvia Rita, Puma, Adriana, Di Gregorio, Sandra, Romano, Chiara, Tirrò, Elena, Massimino, Michele, Antolino, Agostino, Siragusa, Sergio, Mannina, Donato, Impera, Stefana, Musolino, Caterina, Mineo, Giuseppe, Martino, Bruno, Zammit, Valentina, Di Raimondo, Francesco, Manzella, Livia, Stagno, Fabio, Vigneri, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700306/
https://www.ncbi.nlm.nih.gov/pubmed/31456947
http://dx.doi.org/10.3389/fonc.2019.00764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700306/
https://www.ncbi.nlm.nih.gov/pubmed/31456947
http://dx.doi.org/10.3389/fonc.2019.00764

Ejemplares similares